Albemarle Makes Final Proposal for the Acquisition of Liontown

Australian lithium miner Liontown announced that it has received a revised conditional and non-binding indicative proposal from Albemarle to acquire all of the ordinary shares outstanding in Liontown for A$3.00 in cash per share via scheme of arrangement. The revised proposal values Liontown at A$6.6 billion ($4.3 billion) on an equity value basis.

The new cash offer of A$3 per share represents a 14.5% premium to Liontown's last closing price of A$2.62 on Sept. 1 and is 20% higher than Albemarle's offer of A$2.50 per share, which the company rejected as too low in late March.

Albemarle said that the revised indicative proposal is its best and final proposal, in the absence of a superior proposal.

Liontown confirmed that, subject to entry into a mutually acceptable non-disclosure and exclusivity agreement, its board intends to unanimously recommend that shareholders vote in favor of the new offer in the absence of a better offer and after an independent expert has reviewed the deal.

Source: Liontown Resources
Source: Liontown Resources

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.